Fabian F Pusch, Heathcliff Dorado Garcia, Robin Xu, Dennis Gürgen, Yi Bei, Lotte Brückner, Claudia Röefzaad, Jennifer von Stebut, Victor Bardinet, Rocío Chamorro Gonzalez, Angelika Eggert, Johannes H Schulte, Patrick Hundsdörfer, Georg Seifert, Kerstin Haase, Beat W Schäfer, Marco Wachtel, Anja A Kühl, Michael V Ortiz, Antje M Wengner, Monika Scheer, Anton G Henssen
The small molecule inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), elimusertib, is currently being tested clinically in various cancer entities in adults and children. Its preclinical anti-tumor activity in pediatric malignancies, however, is largely unknown. We here assessed the preclinical activity of elimusertib in 38 cell lines and 32 patient-derived xenograft (PDX) models derived from common pediatric solid tumor entities. Detailed in vitro and in vivo molecular characterization of the treated models enabled the evaluation of response biomarkers...
December 30, 2023: Molecular Cancer Therapeutics